SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) — Industry research platform VBData recently highlighted \u201cXingShi\u201d Large Language Model (\u201cXS LLM\u201d) from Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, as one of China\u2019s most anticipated healthcare AI models for 2026.<\/p>\n
The \u201cXingShi\u201d Large Language Model (\u201cXS LLM\u201d) integrates five intelligent agents \u2014 knowledge services, triage, pre-consultation, physician support and electronic medical records \u2014 into a closed-loop system covering the full chronic disease management cycle, an approach that has drawn international attention including coverage by Nature<\/em>.<\/p>\n As one of the earliest domestic models developed alongside the emergence of OpenEvidence, XS LLM is powered by more than 1.1 million articles from over 170 core journals from the database of the Chinese Medical Association, spanning all major clinical disciplines. VBData estimates the model has delivered nearly 400,000 instances of technical assistance to physicians, marking it as a significant tool for clinical support and professional workflows.<\/p>\n Built as the \u201ccore digital brain\u201d of Fangzhou\u2019s platform, XS LLM powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product addresses distinct clinical and patient-side use cases, enabling real-time, precision interventions across medication guidance, patient education, diagnostic assistance, and medical reference.<\/p>\n XS LLM was previously featured by Nature <\/em>News section under the headline \u201cA Chinese AI tool can manage chronic disease \u2014 could it revolutionize health care?\u201d, and the article explored the model\u2019s development, alongside expert views on its potential impact for improving chronic disease management.<\/p>\n Other models cited by VBData include offerings from JD Health, Ant Group and Tencent Health. VBData noted that leading domestic medical AI models are increasingly optimized for China-specific clinical guidelines, reimbursement frameworks and regulatory requirements in order to meet to meet ambitious national targets for broad development of medical AI models by 2027 and near-universal intelligent clinical assistance in primary care by 2030.<\/p>\n Looking ahead, Fangzhou will continue to deepen AI integration across chronic disease services, and broaden access to professional, technology-enabled care while reinforcing its position as a key player in the country\u2019s healthcare digitization drive.<\/p>\n About VBData<\/strong>
Founded in 2014, VBData is an industry information accelerator platform that builds a business case library through in-depth analysis, deconstructs sectors with systematic research, and fosters industry collaboration through dedicated services.<\/p>\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/ZjQ3Yzc0NjItOTJhOS00MGY5LWJmMjgtOGQ4YmE4YzY2YjdhLTEzMDcxNzctMjAyNi0wMi0xMC1lbg==\/tiny\/Fangzhou-Inc-.png\")
\n <\/div>\n","protected":false},"excerpt":{"rendered":"